Amvis Holdings completed the sale of 47 Ishin-kan hospice facilities, mostly in western Japan, to NSSK on 16 November for ¥17.4bn, and its results presentation shows what the company looks like afterwards: smaller, less loss-making in the west, and carrying far less net debt on paper. Earlier Tokyo Brief coverage covers the original announcement.
The sale closed, the gain is scheduled for next year
The sale followed an extraordinary shareholders' meeting on 13 November, after a share purchase agreement on 28 September. Amvis expects a gain of about ¥7.9bn, which it plans to record in the year to September 2027, not in the results just reported. The presentation refers readers to a 28 September notice on the establishment of a subsidiary, an absorption-split into it and the transfer of that subsidiary's shares for full terms.
Amvis says the 47 facilities produced about ¥13bn of sales and an operating loss of ¥250mn in the year to September 2026. The 91 it keeps, in the Tokyo area and eastern Japan, produced ¥36bn of sales and ¥3.5bn of operating profit.
Net profit up, everything above it down
For the year to September 2027, Amvis forecasts revenue of ¥35.6bn, down 29.0% from ¥50.1bn, and operating profit of ¥1.1bn, down 72.8% from ¥4.04bn. Net profit is forecast at ¥5.3bn, against ¥1.28bn, because of the disposal gain.
| Metric | Year to Sept 2026 (actual) | Year to Sept 2027 (forecast) | Change |
|---|---|---|---|
| Revenue | ¥50.1bn | ¥35.6bn | (29.0%) |
| Operating profit | ¥4.04bn | ¥1.1bn | (72.8%) |
| Net profit | ¥1.28bn | ¥5.3bn | +315.0% |
The Ishin-kan business carries the decline. Amvis forecasts segment sales of ¥34.0bn and operating profit of ¥50mn, citing the full-year effect of the medical fee revision, the western sale and a weak first half for occupancy as staffing is rebuilt. It expects a gradual second-half recovery as April hires arrive. It plans five openings, mainly in the Tokyo area and eastern Japan, and expects 96 facilities with capacity for 5,115 residents at the end of September 2027.
The smaller comprehensive medical support segment, which consults for and lends to struggling hospitals, is forecast to grow. Amvis projects sales of ¥1.6bn and operating profit of ¥1.05bn, up from ¥1.2bn and ¥773mn.
Debt reduction is a projection
Amvis's estimate cuts net debt from ¥28.8bn at the end of September 2026 to ¥2.9bn after the transaction. The company breaks the change into ¥8.8bn of borrowings passing to the buyer, ¥100mn less lease debt and ¥17.0bn more cash. It defines net debt as interest-bearing debt plus lease liabilities minus cash. Amvis also says it plans to repay all borrowings with the sale proceeds. That is a plan, not a completed repayment.
The year just ended
For the year to September 2026, Amvis reported revenue of ¥50.1bn, up 1.9%, and operating profit of ¥4.04bn, down 34.5%. Net profit fell 65.1% to ¥1.28bn after a ¥2.1bn impairment loss on some Ishin-kan facilities. Revenue reached 96.9% of the original forecast, issued before the revision of 9 November. It plans to hold the dividend at ¥4 a share.
